TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00751478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-01
Description: ALO-01 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-01
Description: ALO-01 capsules
Study: NCT03195608

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will practice their driving on a driving simulator with feedback form a trained interventionist.
Study: NCT00751478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSIR
Description: immediate release morphine sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02589288

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Infusion of ropivacaine 0.2%
Description: Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automatic Intermittent Bolus of ropivacaine 0.2%
Description: Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
Study: NCT01631968

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cement without antibiotic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cement with erytromycin and colistin.
Study: NCT03245918

Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant Capsule 125 MG
Description: Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period

Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant oral suspension 20 mg/mL
Description: Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
Study: NCT03914625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IV or IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IV or IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study: NCT01389466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Step 2
Description: Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
Study: NCT03596736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elbow Hemiarthroplasty
Study: NCT03596736

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Elbow Arthroplasty
Study: NCT03058172

Intervention type: OTHER
Group type: OTHER
Intervention: Odor presentation (for participants' perception)
Description: Several different odors will be diffused by an olfactometer under the participants' nostrils, though a controlled airflow, and synchronously with the participants' respiration. fMRI designs require repeated stimulus presentation. Odors will also be presented (in flasks or in odor pens) outside the scanner.

Intervention type: OTHER
Group type: OTHER
Intervention: Image presentation (for participants' perception)
Description: Several different pictures will be displayed in front of the participants' face, though a through a mirror system in the scanner, or on a computer screen outside the scanner.
Study: NCT03111355

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazil nut
Description: one nut a day for 2 months, no intervention for 2 months
Study: NCT01347866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: PF-05212384 intravenous infusion weekly starting at 110 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: PF-05212384 intravenous infusion weekly starting at 95 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
Study: NCT00899470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Saxagliptin and Metformin IR, Fasted
Description: Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Saxagliptin and Metformin IR, Fasted
Description: Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Saxagliptin and Metformin IR, Fasted
Description: Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
Study: NCT01508754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure treatment
Description: Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
Study: NCT03605199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.
Study: NCT03634904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug bood sampling
Description: Total: 6 per patient~* after the first administration of ceftazidime (loading dose): sampling #1: at trough before 1st dialysis; sampling #2: after the end of the dialysis session;~* after the second administration of ceftazidime (maintenance dose): sampling #3: at trough before 2d dialysis session;~* after the third administration of ceftazidime (maintenance dose): sampling #4: at trough before 3d dialysis session;~* after the fourth third administration of ceftazidime (maintenance dose): sampling #5: at trough before 4th dialysis session; sampling #6: after the end of the dialysis session
Study: NCT02322684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q
Description: Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q
Description: Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
Study: NCT00384176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: oral tablet once daily
Study: NCT03905395

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation and mindfulness
Description: Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
Study: NCT01560442

Intervention type: DRUG
Intervention: Buprenorphine and Methadone Hydrochloride
Description: To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
Study: NCT00384176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil ( in FOLFOX)
Description: intravenous infusion
Study: NCT03914625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine Oral Suspension
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine Oral Suspension
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine Oral Suspension
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine Oral Suspension
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine Oral Suspension
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine Oral Suspension
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine Oral Suspension
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or IV
Study: NCT00384176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil ( in FOLFOX)
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin (in FOLFOX)
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (in FOLFOX)
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin (in FOLFOX)
Description: intravenous infusion
Study: NCT01381718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT03914625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM
Study: NCT03453190

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Apremilast and Clobetasol
Description: Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.
Study: NCT00384176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (in FOLFOX)
Description: intravenous infusion
Study: NCT00071422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INGAP-Peptide
Description: 1.5 mL, once daily, self-administered SC injection for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INGAP-Peptide
Description: 1.5 mL, once daily, self-administered SC injection for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Study: NCT03914625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO or IV
Study: NCT02489565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
Study: NCT03914625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study: NCT01401257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT3003 Low dose
Description: Liquid,5 ml, twice a day, 12-month treatment
Study: NCT03914625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study: NCT03544736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Experimental: Nivolumab
Study: NCT02572895

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry extract
Description: The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry extract
Description: The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
Study: NCT03544736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Experimental: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Experimental: Nivolumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT03914625

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo cranial radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo testicular radiation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO
Study: NCT02379390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel XRP6258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study: NCT01401257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT3003 Intermediate Dose
Description: Liquid,5 ml, twice a day, 12-month treatment
Study: NCT02379390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT02721251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: 16 week. the goal is 10% weight loss.
Study: NCT01401257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT3003 High Dose
Description: Liquid,5 ml, twice a day, 12-month treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid,5 ml, twice a day, 12-month treatment
Study: NCT01618188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
Study: NCT02721251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Weight Loss
Description: Combined exercise and weight loss components of the other arms
Study: NCT01618188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
Study: NCT02151812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agent Paclitaxel-coated balloon
Description: After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent® Please Paclitaxel-coated Balloon
Description: After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
Study: NCT02161120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Finnish rye bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP rye bread
Study: NCT02139917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional community based palliative care
Description: transitional palliative care include:-~* telephone follow up for early identification of signs and symptoms~* relief of signs and symptoms encountered~* home visit with spiritual support
Study: NCT03413137

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal mpMRI-US Fusion prostate biopsy
Description: mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal mpMRI-US Fusion prostate biopsy
Description: mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal mpMRI-US Fusion prostate biopsy
Description: using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal mpMRI-US Fusion prostate biopsy
Description: using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.
Study: NCT02038231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Mindfully Program
Description: see Arm Description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education Program
Description: See Arm Description.